279 related articles for article (PubMed ID: 12707251)
1. Prevention of cardiovascular ischemic events: high-risk and secondary prevention.
Genest J; Pedersen TR
Circulation; 2003 Apr; 107(15):2059-65. PubMed ID: 12707251
[No Abstract] [Full Text] [Related]
2. [Efficacy of angiotensin-converting enzyme inhibitors in secondary prevention].
Ceconi C; Mastrorilli F; Squasi PA; Gaitani S; Guardigli G; Ferrari R
Ital Heart J; 2005 Nov; 6 Suppl 7():5S-13S. PubMed ID: 16485512
[TBL] [Abstract][Full Text] [Related]
3. Cardiovascular risk in patients with type 2 diabetes.
Shanks M; Holmes DT; Cermakova L; Frohlich J
CMAJ; 2005 Apr; 172(9):1160-1. PubMed ID: 15851694
[No Abstract] [Full Text] [Related]
4. Inhibition of the renin-angiotensin-aldosterone system to prevent ischemic and atherothrombotic events.
Papademetriou V
Am Heart J; 2009 Jun; 157(6 Suppl):S24-30. PubMed ID: 19450721
[TBL] [Abstract][Full Text] [Related]
5. Secondary prevention of ischaemic cardiac events.
Gami A
Clin Evid; 2006 Jun; (15):195-228. PubMed ID: 16973010
[No Abstract] [Full Text] [Related]
6. [Appropriate pharmacological therapy after surgical or percutaneous myocardial revascularization].
Faggiano P; De Feo S; Frattini S; Tramarin R; Dei Cas L
G Ital Cardiol (Rome); 2010 May; 11(5 Suppl 3):116S-120S. PubMed ID: 20879496
[No Abstract] [Full Text] [Related]
7. ASCOT - more than a horse race!
Kjeldsen SE; Narkiewicz K; Hedner T
Blood Press; 2005; 14(5):262-3. PubMed ID: 16257870
[No Abstract] [Full Text] [Related]
8. The HOPE study: comparison with other trials of secondary prevention.
Otterstad JE; Sleight P
Eur Heart J; 2001 Aug; 22(15):1307-10. PubMed ID: 11465962
[No Abstract] [Full Text] [Related]
9. Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)--can C-reactive protein be used to target statin therapy in primary prevention?
Mora S; Ridker PM
Am J Cardiol; 2006 Jan; 97(2A):33A-41A. PubMed ID: 16442935
[TBL] [Abstract][Full Text] [Related]
10. The need for wider and appropriate utilization of aspirin and statins in the treatment and prevention of cardiovascular disease.
Hennekens CH; Schneider WR
Expert Rev Cardiovasc Ther; 2008 Jan; 6(1):95-107. PubMed ID: 18095910
[TBL] [Abstract][Full Text] [Related]
11. [Dyslipidemia management in patients with impaired glucose tolerance].
Asano M; Yamada N
Nihon Rinsho; 2005 Feb; 63 Suppl 2():538-42. PubMed ID: 15779437
[No Abstract] [Full Text] [Related]
12. Cardiovascular disease prevention using fixed dose pharmacotherapy in Iran: updated meta-analyses and mortality estimation.
Sepanlou SG; Farzadfar F; Jafari E; Danaei G
Arch Iran Med; 2012 Sep; 15(9):531-7. PubMed ID: 22924369
[TBL] [Abstract][Full Text] [Related]
13. Tissue ACE inhibitors for secondary prevention of cardiovascular disease in patients with preserved left ventricular function: a pooled meta-analysis of randomized placebo-controlled trials.
Saha SA; Molnar J; Arora RR
J Cardiovasc Pharmacol Ther; 2007 Sep; 12(3):192-204. PubMed ID: 17875946
[TBL] [Abstract][Full Text] [Related]
14. Drug insight: the role of statins in combination with ezetimibe to lower LDL cholesterol.
Gotto AM; Farmer JA
Nat Clin Pract Cardiovasc Med; 2006 Dec; 3(12):664-72. PubMed ID: 17122799
[TBL] [Abstract][Full Text] [Related]
15. [Pharmacotherapy after cardiac infarction].
Darius H; Meyer J
Internist (Berl); 2001 May; 42(5):699-712. PubMed ID: 11400577
[No Abstract] [Full Text] [Related]
16. A "poly-portfolio" for secondary prevention: a strategy to reduce subsequent events by up to 97% over five years.
Robinson JG; Maheshwari N
Am J Cardiol; 2005 Feb; 95(3):373-8. PubMed ID: 15670547
[TBL] [Abstract][Full Text] [Related]
17. The importance of managing cardiovascular risk in the treatment of hypertension: the role of ACE inhibitors and ARBs.
Pierson CA; Epstein BJ; Roberts ME
J Am Acad Nurse Pract; 2008 Nov; 20(11):529-38. PubMed ID: 19128336
[No Abstract] [Full Text] [Related]
18. Lipoprotein management in patients with cardiometabolic risk: consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation.
Brunzell JD; Davidson M; Furberg CD; Goldberg RB; Howard BV; Stein JH; Witztum JL
J Am Coll Cardiol; 2008 Apr; 51(15):1512-24. PubMed ID: 18402913
[No Abstract] [Full Text] [Related]
19. Re: Secondary medical prevention in patients with peripheral arterial disease.
Schouten O; Welten GM; Bax JJ; Poldermans D
Eur J Vasc Endovasc Surg; 2008 Jan; 35(1):59-60. PubMed ID: 17719805
[No Abstract] [Full Text] [Related]
20. The editor's roundtable: the JUPITER trial--initial results and clinical implications.
Ridker PM; Friedewald VE; Davidson MH; Willerson JT; Roberts WC
Am J Cardiol; 2009 May; 103(10):1417-25. PubMed ID: 19427439
[No Abstract] [Full Text] [Related]
[Next] [New Search]
